Total submissions: 7
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Counsyl | RCV000410954 | SCV000487745 | likely pathogenic | Diastrophic dysplasia | 2016-10-19 | criteria provided, single submitter | clinical testing | |
Counsyl | RCV000412069 | SCV000487746 | likely pathogenic | Multiple epiphyseal dysplasia type 4 | 2016-10-19 | criteria provided, single submitter | clinical testing | |
Counsyl | RCV000409656 | SCV000487747 | likely pathogenic | Atelosteogenesis type II | 2016-10-19 | criteria provided, single submitter | clinical testing | |
Counsyl | RCV000411101 | SCV000487748 | likely pathogenic | Achondrogenesis, type IB | 2016-10-19 | criteria provided, single submitter | clinical testing | |
Invitae | RCV002524629 | SCV003257209 | pathogenic | Achondrogenesis, type IB; Atelosteogenesis type II; Multiple epiphyseal dysplasia type 4; Diastrophic dysplasia | 2022-07-11 | criteria provided, single submitter | clinical testing | Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may create or strengthen a splice site. ClinVar contains an entry for this variant (Variation ID: 371783). This variant has not been reported in the literature in individuals affected with SLC26A2-related conditions. This variant is not present in population databases (gnomAD no frequency). This sequence change creates a premature translational stop signal (p.Thr603Serfs*5) in the SLC26A2 gene. While this is not anticipated to result in nonsense mediated decay, it is expected to disrupt the last 137 amino acid(s) of the SLC26A2 protein. This variant disrupts a region of the SLC26A2 protein in which other variant(s) (p.Ala715Val) have been determined to be pathogenic (PMID: 8571951, 21077204, 21922596; Invitae). This suggests that this is a clinically significant region of the protein, and that variants that disrupt it are likely to be disease-causing. For these reasons, this variant has been classified as Pathogenic. |
Institute of Medical Genetics and Applied Genomics, |
RCV000411101 | SCV004171030 | pathogenic | Achondrogenesis, type IB | 2023-11-23 | criteria provided, single submitter | clinical testing | |
Baylor Genetics | RCV000411101 | SCV004201772 | pathogenic | Achondrogenesis, type IB | 2023-06-01 | criteria provided, single submitter | clinical testing |